Thermo Fisher Scientific (TMO) Investor Day 2026 summary

Strategic positioning and market outlook

• Positioned as an industry leader with a $45B revenue base, over 125,000 employees, and a comprehensive portfolio across pharma, biotech, diagnostics, and advanced materials, serving a $250B–$255B end market with under 20% share and strong long-term fundamentals driven by demographics and AI advancements.

• End markets are improving, with pharma and biotech showing renewed growth due to increased funding, M&A, and R&D reinvestment, especially in biologics and GLP-1s, and significant U.S. manufacturing investments.

• AI and automation are seen as major tailwinds, enhancing R&D productivity, accelerating drug development, and driving demand for wet lab validation and data generation, with unique positioning to benefit from these trends.

• Emerging markets, particularly China, India, and Brazil, are expected to contribute to long-term growth, with China’s pharma and biotech segment performing strongly.

• The company is actively managing its portfolio, including recent acquisitions (Clario, Solventum) and divestitures, to strengthen its position in high-growth segments.

Growth strategy and innovation

• Growth strategy centers on high-impact innovation, trusted partner status, and an unparalleled commercial engine, supported by $1.4B annual R&D investment and over 7,000 R&D staff.

• Proteomics, precision medicine, and semiconductor solutions are highlighted as fast-growing, differentiated businesses, with strong customer adoption and integration of AI and digital partnerships (OpenAI, NVIDIA).

• The Accelerator Drug Development program integrates CRO and CDMO services, leveraging data and AI to streamline clinical trials and drug development, driving share gains.

• Commercial infrastructure includes the largest industry sales force, global supply chain, and leading e-commerce platforms, enabling deep customer engagement and share gain.

• Automation and productized solutions are being developed to meet rising demand for data generation and lab efficiency, especially as data factories become more prevalent.

Financial performance and guidance

• Achieved a 10% revenue CAGR and 12% adjusted EPS CAGR from 2015 to 2025, with free cash flow growing at 10% CAGR.

• 2026 guidance: $47.3B–$48.1B revenue, 3%–4% organic growth, 70 bps margin expansion, adjusted EPS of $24.64–$25.12 (8%–10% growth), and free cash flow of $6.9B–$7.4B.

• Midterm (2026–2027) outlook targets 3%–6% organic growth, 50–70 bps annual margin expansion, and high single-digit adjusted operating income growth.

• Long-term model assumes 7% organic revenue CAGR, 40–50 bps annual margin expansion, and low teens EPS and free cash flow growth, driven by share gains and end market normalization.

• Pharma and biotech expected to be high single-digit growth markets, with share gains from integrated offerings and AI-driven productivity.